200 related articles for article (PubMed ID: 29417252)
1. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
Wu Z; Yang X; Chen L; Wang Z; Shi Y; Mao H; Dai G; Yu X
Medicine (Baltimore); 2017 May; 96(20):e6731. PubMed ID: 28514289
[TBL] [Abstract][Full Text] [Related]
4. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
[TBL] [Abstract][Full Text] [Related]
5. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
7. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound.
Schirin-Sokhan R; Winograd R; Roderburg C; Bubenzer J; do Ó NC; Guggenberger D; Hecker H; Trautwein C; Tischendorf JJ
World J Gastroenterol; 2012 Feb; 18(6):541-5. PubMed ID: 22363120
[TBL] [Abstract][Full Text] [Related]
8. Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.
Tranquart F; Dujardin PA; Bouché O; Marcus C; Borg C; Manzoni P; Douillard JY; Labbe-Devilliers C; Terrebonne E; Smith D; Trillaud H; Capitain O; Aubé C; Spano JP; Lucidarme O; Ferru A; Tasu JP; Manfredi S; Bleuzen A; Léger J; Lecomte T
Ultraschall Med; 2018 Oct; 39(5):544-558. PubMed ID: 29232725
[TBL] [Abstract][Full Text] [Related]
9. Comparison of contrast-enhanced ultrasonograpy with Gd-EOB-DTPA-enhanced MRI in the diagnosis of liver metastasis from colorectal cancer.
Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Kikuchi Y; Otsuka Y; Kaneko H; Igarashi Y; Sumino Y
J Clin Ultrasound; 2017 Mar; 45(3):138-144. PubMed ID: 27861987
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Evaluation of Combretastatin A4 Phosphate Early Efficacy in a Tumor Model with Dynamic Contrast-Enhanced Ultrasound.
Zhang P; Chen Y; Liu J; Yang Y; Lv Q; Wang J; Zhang L; Xie M
Ultrasound Med Biol; 2018 Apr; 44(4):840-852. PubMed ID: 29395676
[TBL] [Abstract][Full Text] [Related]
12. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
13. Value of Perfusion Parameters for Differentiating Hepatocellular Carcinoma and Liver Metastasis With Hypervascularity and a Normal Hepatic Background on Contrast-Enhanced Ultrasound Imaging.
Lu Q; Zhang XL; Han H; Huang BJ; Ding H; Wang WP
J Ultrasound Med; 2019 Oct; 38(10):2601-2608. PubMed ID: 30697787
[TBL] [Abstract][Full Text] [Related]
14. A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination.
Kitamura H; Koike S; Nakazawa K; Matsumura H; Yokoi K; Nakagawa K; Arai M
J Surg Oncol; 2013 Feb; 107(2):155-9. PubMed ID: 22903532
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
Cheng J; Qiu M; Zhang Y; Hong N; Shen D; Zhou J; Wang Y
AJR Am J Roentgenol; 2020 Dec; 215(6):1377-1383. PubMed ID: 32991216
[No Abstract] [Full Text] [Related]
16. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of atypical hepatic hemangioma from liver metastases: Diagnostic performance of a novel type of color contrast enhanced ultrasound.
Wu XF; Bai XM; Yang W; Sun Y; Wang H; Wu W; Chen MH; Yan K
World J Gastroenterol; 2020 Mar; 26(9):960-972. PubMed ID: 32206006
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
19. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Tampellini M; Gned D; Baratelli C; Brizzi MP; Ottone A; Alabiso I; Bertaggia C; Di Maio M; Scagliotti GV; Veltri A
Radiol Med; 2016 Dec; 121(12):950-957. PubMed ID: 27601143
[TBL] [Abstract][Full Text] [Related]
20. Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases-preliminary study.
Matsushima S; Sato T; Nishiofuku H; Sato Y; Murata S; Kinosada Y; Era S; Inaba Y
Clin Imaging; 2017; 41():1-6. PubMed ID: 27721090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
